TrialJournal of neurology2022

Quantitative magnetic resonance imaging measures as biomarkers of disease progression in boys with Duchenne muscular dystrophy: a phase 2 trial of domagrozumab.

Sarah P Sherlock et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.